12-Month OMNI data from the prospective, multicenter GEMINI clinical trial show statistically significant postoperative reductions in mean IOP and suppression of daily IOP fluctuations MENLO PARK, ...
Sight Sciences SGHT recently announced the publication of a systematic literature review and meta-analysis in the European Journal of Ophthalmology, highlighting the long-term safety and efficacy of ...
“The growth and adoption of OMNI as a standalone treatment as evidenced by such a diverse and esteemed panel of speakers sharing their real-world experiences and clinical data, brings a sense of great ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Canaloplasty and trabeculotomy helped control IOP over 2 ...
MENLO PARK, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. A study looked at real-world outcomes with Omni, Hydrus, ...
MENLO PARK, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing ...
Sight Sciences Inc. (NASDAQ:SGHT) on Tuesday announced that UnitedHealthcare has updated its Glaucoma Surgical Treatments policy to cover goniotomy, trabeculotomy, canaloplasty (ab interno), and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback